Trial Profile
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Interleukin-15 (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 15 Feb 2022 Status changed from completed to discontinued.
- 31 Dec 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2021 Status changed from suspended to active, no longer recruiting.